Intrauterine exposure to maternal opioid maintenance treatment and associated risk factors may impair child growth
Acta Paediatrica · 2024
DOI: 10.1111/apa.17198 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Paediatrica, 2024. Verfasst von Minna Kanervo und 5 weiteren Autor:innen. Beteiligte Einrichtung: University of Helsinki Doctoral School, Helsinki, Finland. Hauptthemen laut MEDLINE: Opiate Substitution Treatment, Prenatal Exposure Delayed Effects, Opioid-Related Disorders, Child Development. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Päivikki ja Sakari Sohlbergin Säätiö, Maija Sulamaan säätiö, Lastentautien Tutkimussäätiö.
Abstract (Originalsprache)
Aim
How maternal opioid maintenance treatment (OMT) affects children is under‐researched. This population‐based registry study investigated child growth and somatic health following intrauterine exposure to this treatment.
Methods
Children born between 1 March 2011 and 30 May 2021 to mothers who used buprenorphine, buprenorphine‐naloxone, or methadone throughout their pregnancies were followed for 2 years at the Helsinki University Hospital, Finland. Appropriate statistical tests were used to compare the treatment groups.
Results
Of the 67 neonates, 52% were male, 96% were born full‐term and 63% were treated for neonatal opioid withdrawal syndrome. Otherwise, the children were predominantly healthy, although relatively small: 22% were small for gestational age, the methadone group children being the smallest. Foetal exposure to maternal methadone treatment, illicit drugs, hepatitis C and smoking were associated with small for gestational age; the former two were also associated with later slower growth, especially head growth and weight gain ( p < 0.001). However, 29% were overweight at 2 years.
Conclusion
Using child growth as the outcome, we found that buprenorphine‐naloxone and buprenorphine‐monotherapy had equal effects as forms of maternal OMT. Exposure to multiple risk factors may harm foetal and subsequent growth. We recommend long‐term follow‐up of children exposed to maternal OMT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Helsinki Doctoral School, Helsinki, Finland.
- Pediatric Research Center, Children's Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
- Gynecology and Obstetrics, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
ORCID-Profile: Minna Kanervo
Förderung
- Päivikki ja Sakari Sohlbergin Säätiö
- Maija Sulamaan säätiö
- Lastentautien Tutkimussäätiö
Zitieren
APA
Kanervo, M., Luoto, L., Tupola, S., Nikkola, E., Kahila, H., & Rantakari, K. (2024). Intrauterine exposure to maternal opioid maintenance treatment and associated risk factors may impair child growth. Acta Paediatrica. https://doi.org/10.1111/apa.17198
Vancouver
Kanervo M, Luoto L, Tupola S, Nikkola E, Kahila H, Rantakari K. Intrauterine exposure to maternal opioid maintenance treatment and associated risk factors may impair child growth. Acta Paediatrica. 2024. doi:10.1111/apa.17198
BibTeX
@article{Kanervo2024,
author = {Kanervo, Minna and Luoto, Liina and Tupola, Sarimari and Nikkola, Eeva and Kahila, Hanna and Rantakari, Krista},
title = {Intrauterine exposure to maternal opioid maintenance treatment and associated risk factors may impair child growth},
journal = {Acta Paediatrica},
year = {2024},
doi = {10.1111/apa.17198}
}
EUVIMED